<DOC>
	<DOCNO>NCT00205465</DOCNO>
	<brief_summary>To evaluate safety tolerability VX-765 subject chronic plaque psoriasis treat 28 day .</brief_summary>
	<brief_title>Phase 2 Clinical Study Psoriasis With Oral Investigational Drug VX-765</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Diagnosed chronic plaque psoriasis least 6 month Prior systemic therapy Current prior history illness precluding use immunomodulatory therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>